Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessArthur J. Gallagher’s Investor Day Review

Arthur J. Gallagher’s Investor Day Review

Add to Favorite
Added to Favorite


RBC Capital provided a review of Arthur J. Gallagher & Co. (NYSE:AJG) quarterly Investor Day, which offered up some data points indicating that organic growth trends have remained favorable to start the year.
Both P&C pricing and the economy aren’t showing signs of fading in any meaningful way and remain tailwinds. Gallagher’s M&A appetite remains high as evidenced by recent deal activity. Likewise, the company sounded upbeat about 2023 organic growth prospects across both segments.
The analysts said they remain constructive on the company’s shares at current levels and revised their 2023 EPS estimate to $8.70 from $8.75 to reflect higher interest expense from a recent debt offering. Their 2024 EPS forecast of $9.70 is unchanged.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Thermo Fisher Scientific Reports Better Than Expected Q1 Results

Thermo Fisher Scientific (NYSE:TMO) announced its first-quarter earnings and...

Humana Drops 5 percent Despite Q1 Beat

Humana (NYSE:HUM) saw its shares drop by around 5%...